Dr. Snyder is one of many physicians around the world who have been utilizing Apligraf to treat chronic wounds after traditional therapies have failed. As the medical director of the St. Francis Hospital Wound Care Center in Los Angeles, Dr. Snyder has treated a number of patients with Apligraf for chronic, non-healing wounds.
"Conventional wound care, consisting of infection control, cleaning, and keeping pressure off the wound and other such basic approaches, can often close these wounds," noted Dr. Snyder. "However, a large portion of these chronic wounds fail to heal, and a more active approach is needed."
Venous leg ulcers and diabetic foot ulcers are among the most frequently occurring chronic wounds, affecting nearly two million people every year in the U.S. Up to 12 percent of diabetics have a history of foot ulcers, and 85 percent of lower-limb amputations among diabetic patients are preceded by DFUs.
More than 600,000 new cases of venous leg ulcers are reported annually, many among diabetics.
In creating its DTC ads, Organogenesis conducted extensive market research,
including a survey of patients, caregivers and wound care nurses. The survey found that patients often view their wounds with greater concern than their other major co-morbidities, including high blood pressure and diabetes. The company's survey results are consistent with a 2002 survey by the American Diabetes Association, which revealed that one out of every two Americans with diabetes has never heard of or knows little about diabetic foot ulcers.
"Our research showed that, unfortunately, many of these patients are
also unaware of advanced treatment options,"
|SOURCE Organogenesis, Inc.|
Copyright©2008 PR Newswire.
All rights reserved